8-K: Allogene Therapeutics Expands Market Reach and Advances Clinical Programs in Q1 2024

Allogene Therapeutics reports Q1 2024 financial results, expands its oncology rights to include all EU member states and the UK, and provides updates on its clinical programs.

Summary

• Allogene Therapeutics announced its first quarter 2024 financial results and provided a business update.
• The company has expanded its CD19 oncology rights to include all EU member states and the United Kingdom, increasing the potential market opportunity to over $9.5 billion.
• The pivotal Phase 2 ALPHA3 trial for cema-cel in Large B Cell Lymphoma is expected to begin in mid-2024, with efficacy analyses expected in 2026.
• Initial data from the Phase 1 trial of cema-cel in relapsed/refractory Chronic Lymphocytic Leukemia is expected by the end of 2024.
• Allogene plans to submit an Investigational New Drug application for ALLO-329 in autoimmune disease in Q1 2025, with proof-of-concept data expected by the end of 2025.
• The company received a $15 million grant from the California Institute for Regenerative Medicine to support the TRAVERSE trial for ALLO-316 in Renal Cell Carcinoma.
• Allogene ended Q1 2024 with $397.3 million in cash, cash equivalents, and investments, projecting a cash runway into 2026.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024.
• GAAP operating expenses are expected to be approximately $300 million, including $60 million in non-cash stock-based compensation.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant progress in clinical programs and market expansion, but also acknowledges financial losses and future cash burn. The sentiment is cautiously optimistic.

Positives

• The expansion of CD19 oncology rights significantly increases the potential market opportunity for Allogene's products.
• The ALPHA3 trial has the potential to establish cema-cel as a standard treatment for patients with minimal residual disease after initial lymphoma treatment.
• The $15 million grant from CIRM provides additional funding for the development of ALLO-316 in Renal Cell Carcinoma.
• The company's cash runway is projected into 2026, providing financial stability for ongoing research and development.
• The development of ALLO-329 with Dagger technology has the potential to eliminate the need for lymphodepletion in autoimmune disease treatment.

Negatives

• The company experienced a net loss of $65 million in the first quarter of 2024.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024.
• The company's GAAP operating expenses are expected to be approximately $300 million for 2024.

Risks

• Clinical trial outcomes may materially change as more patient data becomes available.
• There is no guarantee that Foresight will successfully develop an MRD assay for use as a companion diagnostic with cema-cel.
• The company may encounter difficulties enrolling patients in clinical trials.
• The company may not be able to demonstrate the safety and efficacy of its product candidates in clinical trials.
• Challenges with manufacturing or optimizing manufacturing of product candidates could arise.
• The company may need to obtain additional financing to develop its product candidates and implement its operating plans.

Future Outlook

Allogene expects its cash runway to fund operations into 2026 and anticipates a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024. The company also expects GAAP operating expenses of approximately $300 million for 2024.

Management Comments

• David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene stated that they are proud of the progress made across their portfolio, particularly the transformative potential of the ALPHA3 trial with cema-cel.
• David Chang also mentioned that securing the EU and UK rights reinforces their conviction in the cema-cel program.
• Management believes they are well-positioned to change the CAR T treatment landscape for the benefit of patients.

Industry Context

The expansion of Allogene's market rights and the advancement of its clinical programs reflect the growing interest and investment in allogeneic CAR T cell therapies. The company's focus on both cancer and autoimmune diseases positions it to address significant unmet medical needs in these areas.

Comparison to Industry Standards

• Allogene's focus on allogeneic CAR T therapy differentiates it from companies primarily developing autologous CAR T therapies, such as Gilead's Yescarta and Novartis' Kymriah.
• The expansion of market rights to the EU and UK is a strategic move to compete with global players in the cell therapy market.
• The ALPHA3 trial's design, which includes a novel MRD test and a one-time infusion approach, is innovative compared to standard treatment protocols.
• The development of Dagger technology for autoimmune disease treatment is a novel approach to address the limitations of current CAR T therapies.
• The $15 million grant from CIRM is a significant endorsement of Allogene's research in Renal Cell Carcinoma, comparable to other grants awarded to companies in the regenerative medicine space.

Related Party Transactions

• Collaboration revenue from a related party was $22,000 for the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders may be positively impacted by the expanded market opportunity and clinical progress.
• Employees may benefit from the company's growth and development.
• Patients may benefit from the potential of new and improved treatment options.
• Suppliers and creditors may see increased business opportunities with the company's expansion.

Next Steps

• Initiate the pivotal Phase 2 ALPHA3 trial in mid-2024.
• Release initial data from the Phase 1 ALPHA2 CLL cohort by the end of 2024.
• Provide a Phase 1 data update from the TRAVERSE trial by the end of 2024.
• Submit an IND application for ALLO-329 in Q1 2025.
• Conduct a Phase 2 pivotal study for cema-cel in CLL in 2025.
• Release proof-of-concept data for ALLO-329 by the end of 2025.
• Complete the Independent Data Safety Monitoring Board (IDSMB) interim EFS analysis for the ALPHA3 trial in the first half of 2026.
• Release the primary EFS analysis data for the ALPHA3 trial in the second half of 2026.
• Submit a Biologics License Application (BLA) for cema-cel in 2027.

Key Dates

Keywords

Allogene, CAR T, Cemacabtagene Ansegedleucel, AlloCAR T, Lymphoma, Leukemia, Autoimmune Disease, Renal Cell Carcinoma, Clinical Trial, Biotechnology